Research for other indications is ongoing. In the first trial of microRNA inhibition to treat heart failure, a novel agent did not reduce left ventricular end-systolic volume index at 6 months ...

Credit: Getty Images A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. Beta blockers have long been included in the ...

For patients who present with essential hypertension and further symptoms of possible heart failure, it is important for physicians to consider and treat the patient's underlying disease. A ...

Dr. Patrick Malecha (Medicine): A 69-year-old man with a history of myocardial infarction, ischemic cardiomyopathy, and an implantable cardioverter–defibrillator (ICD) was evaluated because of dyspnea ...

Results from the first randomised trial evaluating microRNA inhibition in heart failure were presented today at Heart Failure 2026.

Empagliflozin reduces heart failure hospitalization risk in patients with acute myocardial infarction, irrespective of type 2 diabetes or chronic kidney disease status. The EMPACT-MI trial showed a 23 ...

For the first time, scientists have shown that heart muscle cells can regrow after a heart attack in humans, a process that ...

It has come to light that there are irregularities in a clinical trial published by The BMJ on 29 October 2025: Prevention of acute myocardial infarction induced heart failure by intracoronary ...

Background Both Takotsubo syndrome (TS) and ST-elevation myocardial infarction (STEMI) are conditions characterised by the ...

Myocardial ischemia is a drop in blood flow to the heart. Myocardial infarction, or heart attack, occurs when death or damage occurs in the muscle tissue of the heart due to low blood supply. The ...